

EVALUATION OF ANTIBIOTIC USE IN SEPTORHINOPLASTY CAUSED BY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS: A CASE REPORT

Ömer Akgül*

Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Van Yüzüncü Yıl University, VAN, Turkey.

Article Received: 14 August 2025 | Article Revised: 4 September 2025 | Article Accepted: 25 September 2025

*Corresponding Author: Ömer Akgül

Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Van Yüzüncü Yıl University, VAN, Turkey.

DOI: <https://doi.org/10.5281/zenodo.17234656>

How to cite this Article: Ömer Akgül (2025) EVALUATION OF ANTIBIOTIC USE IN SEPTORHINOPLASTY CAUSED BY METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS: A CASE REPORT. World Journal of Pharmaceutical Science and Research, 4(5), 186-193. <https://doi.org/10.5281/zenodo.17234656>



Copyright © 2025 Ömer Akgül | World Journal of Pharmaceutical Science and Research.

This work is licensed under creative Commons Attribution-NonCommercial 4.0 International license (CC BY-NC 4.0).

ABSTRACT

Septorhinoplasty is a commonly performed procedure for facial aesthetics and obstructed nasal breathing. There have been only 4 reported cases of methicillin-resistant *Staphylococcus aureus* (MRSA) associated postoperative complications following septorhinoplasty reported in the literature across all specialties. In this article, we report a case of MRSA-associated infection after an uncomplicated septorhinoplasty. Risk stratification and outcome of treatment are described, followed by a review of the current literature. We discuss the epidemiology of MRSA colonization, prophylactic use of antibiotics in septorhinoplasty, previously reported MRSA-associated septorhinoplasty infections, and management of complications. There are no current standards for MRSA decolonization before septorhinoplasty. Finally, we offer recommendations for patients at high risk for MRSA infection undergoing septorhinoplasty and considerations for treatment of MRSA infections should they occur after septorhinoplasty.

KEYWORD: MRSA, Antibiotic resistance, Septorhinoplasty.

INTRODUCTION

Septorhinoplasty is one of the most common ambulatory procedures performed by facial surgeons.^[1,2] Despite increasing nasal colonization with virulent organisms, such as methicillin-resistant *Staphylococcus aureus* (MRSA), infection rates remain less than 2.3% for these procedures without the use of prophylactic antibiotics.^[3-7] Although patients colonized with MRSA are at an increased risk for surgical site infection, few cases of MRSA-associated infections after septorhinoplasty have been reported.^[4,5,8-11]

S. aureus is responsible for the highest rate of nosocomial infections.^[7] Shortly after the introduction of methicillin in the 1960s, *S. aureus* resistance to methicillin developed via acquisition of a *mecA* gene mutation, which encodes penicillin-binding protein 2a.^[9,12,13] In 1983, MRSA prevalence was 5% in large hospitals, but by 1991, prevalence rates in hospitals approached 30%.^{14,15} *S. aureus* colonizes 20% to 30% of the general population, whereas MRSA is found in only 1.5%. Colonization risks are highest in patients with previous MRSA colonization, intensive care unit admissions, hospitalizations in the last 12 months, longterm care facility residency, dialysis or infusion therapy, antibiotic therapy in the last 3 months, hospital admissions for skin or soft tissue infections, and HIV infection.^[16-19] Community-associated MRSA outbreaks have been observed in various populations, such as sports teams, military personnel, and prison inmates.^[20-23] These cases have led to poorly predictive risk factors, including skin trauma, sharing contaminated equipment, intravenous (IV) drug abuse, and incarceration.

One significant consequence of MRSA colonization is the demonstrated risk of surgical site infections.^[8] Health care-associated MRSA (HA-MRSA) infections are defined as those occurring more than 48 hours after hospitalization or outside the hospital in those who have had health care exposure in the previous 12 months.^[24] Community-associated MRSA (CAMRSA) infections are those occurring without prior health care-related exposure. However, the etiology of MRSA infections is becoming increasingly vague as colonization rates rise in the community and as patients are being exposed to an increasing number of risk factors. We present a case of an MRSA-associated infection following an uncomplicated septorhinoplasty performed on an incarcerated male.

CASE REPORT

A 42-year-old incarcerated man presented for an uncomplicated open-approach septorhinoplasty for posttraumatic nasal obstruction caused by multiple nasal fractures. The patient had no significant past medical history other than a smoking history of 0.8 packs per day for 18 years. He had a 74-day history of incarceration after an altercation with police. As a result of that altercation, he sustained a right subcondylar fracture treated 25 days after the injury with open reduction and internal fixation via a transmasseteric approach. Eleven days postoperatively, he presented with incision dehiscence and purulence. After incision and drainage, microbiology culture was obtained, iodoform gauze was packed into the site, and he was placed on a regimen of clindamycin 300 mg four times daily for 1 week. Culture results were suggestive of oral flora, revealing few gram-positive cocci, few gram-negative rods and coccobacilli, and rare gram-negative diplococci. Susceptibility was not obtained but the infection was responsive to clindamycin. The incision healed without complications. Thirty-one days after the resolution of his infection and completion of his clindamycin regimen, he presented for septorhinoplasty.

A single dose of preoperative cefazolin injection (Ancef; GlaxoSmithKline) was provided. The procedure consisted of bilateral osteotomies, dorsal hump reduction, septoplasty, spreader grafts, and tip-defining sutures. A Denver splint was placed, and bacitracin-impregnated Doyle splints were inserted and secured with a single transseptal 2-0 silk suture. Postoperatively, the patient was prescribed the following: acetaminophen/hydrocodone (Norco) and amoxicillin/clavulanate (Augmentin) 500 mg and 125 mg, respectively, every 12 hours for 5 days, and bacitracin to his incisions for 5 days. Follow-up was arranged for 5 days later.

The patient was transferred from the penitentiary to his follow-up appointment on postoperative day 6, which was 1 day later than scheduled. His Denver and Doyle splints were removed. The patient reported that he had not received any of his medications; however, he reported decreased pain and swelling. On examination, the patient exhibited

normal healing without evidence of infection, and the patient returned to the penitentiary. On the postoperative day 11, the patient returned for his follow-up appointment. He was experiencing new pain, increased swelling, and persistent drainage from his nose. Physical examination revealed generalized nasal edema, fluctuance with slight erythema at the nasal base, and purulent drainage from his marginal and columellar incisions. He remained afebrile, and his vital signs were stable. Samples for aerobic, anaerobic, and fungal cultures were obtained from the purulent drainage.

He was admitted to the hospital and placed on IV ampicillin/ sulbactam (Unasyn; Pfizer Inc.). Computed tomography demonstrated the infection was localized to the nasal region without sinus involvement. The patient was taken to the operative suite for incision and drainage under general anesthesia. The marginal and columellar incisions were opened, and the cartilage grafts were removed. After saline irrigation, the incisions were packed with sterile iodoform gauze. The infectious disease service was consulted, and daptomycin 6 mg/kg and piperacillin/tazobactam (Zosyn; Pfizer Inc.) were recommended, pending definitive cultures. Two days later, the patient returned to the operating suite for irrigation and debridement. No purulence was expressed. Plain gauze packing was performed, extending externally through the marginal incisions. The columellar incision was closed to promote cosmesis. The patient continued to improve, and the packing was removed 2 days later.

The cultures demonstrated growth of MRSA, and HIV antibody screening with fourth-generation enzyme-linked immunosorbent assay was negative. The infectious disease service provided the final recommendations of IV daptomycin 6 mg/kg for 4 weeks followed by 2 weeks of oral minocycline. A peripherally inserted central catheter line was placed. He remained an inpatient because the penitentiary was unable to arrange for IV antibiotic administration. One week later, examination revealed well-healed incisions without edema. The patient reported greatly improved breathing without any discomfort compared with his preoperative condition. However, the final cosmetic result involved widening at the nasal base secondary to osteotomy site healing in the presence of underlying tissue edema. At the time of discharge, no evidence of infection was seen. At the 2-week and 2-month follow-up appointments, similar findings were appreciated.

DISCUSSION

A review of the literature revealed 4 previously reported cases of MRSA-associated septorhinoplasty infections, including 2 patients at high risk for MRSA infection and 2 patients without clear risk factors.^[4,9-11] Factors that identified the 2 patients as high risk included extensive health care contact and a prior MRSA-associated infection.^[4,9] One of the 2 patients without identifiable risk factors had an external lateral osteotomy, and the MRSA infection was attributed to the osteotomy site.^[11] Our patient presented with both low-risk and high-risk factors for MRSA colonization because of his incarceration, recent hospitalization, and a recent antibiotic regimen. Of the 4 previously reported cases, 1 patient presented 4 days postoperatively,^[11] 2 patients presented 6 days postoperatively,^[4,10] and our patient presented 11 days postoperatively. There was no consistency among the patients with regard to nasal splinting or packing.

Infections associated with septorhinoplasty are uncommon, attributable to surgery in an anatomic location of high local vascularity and typically performed on a relatively young and healthy population.^[13] The rare instances of infection may be attributed to proliferation of the patient's underlying flora, including previous inoculation with MRSA. Although not specific to MRSA-associated infections after septorhinoplasty, possible local complications include scar formation,

nasal tip droop, septal perforation, and saddle nose deformity, as well as various systemic complications, which are beyond the scope of this review.^[2,25]

Because of the low incidence of MRSA colonization and rarely reported MRSA-associated infections after septorhinoplasty, use of preoperative screening and decolonization is not recommended but will be discussed here for completeness.^[8] It is understood that administration of antibiotics used for widespread decolonization, such as mupirocin, may select for the development of mupirocin-resistant bacterial strains.^[26,27] Mupirocin is a protein synthesis inhibitor, selectively binding bacterial isoleucyl transfer-RNA synthetase.^[27] Its overuse for MRSA is not only selective of resistant strains but also creates more high-level mupirocin resistance in MRSA than in methicillin-sensitive *S. aureus*. However, screening of patients, particularly those at risk for MRSA colonization, allows for targeted therapy, decreased treatment costs, and minimal possible side effects. MRSA can colonize the nares, followed in frequency by the gastrointestinal tract and skin. Nasal MRSA colonization demonstrates an increased risk of MRSA-associated infections. Therefore, nasal MRSA screening is currently the most powerful method in identifying patients at risk for developing MRSA-associated infections.^[8,28-30] MRSA colonizes alternative sites in the absence of nasal colonization, including the oropharynx. In the situation of a negative nasal screening result, oropharyngeal colonization is not excluded and may be a source for development of a subsequent infection.^[31] Materials and techniques employed during screening produce variable results. Swabs with nylon-flocked tips or cellular foam tips have increased MRSA detection rates compared with traditional rayon swabs.^[32] The nasal swabbing technique directly affects detection rates; therefore, use of proper technique is paramount.^[33]

Antibiotic combinations for MRSA decolonization have been evaluated with variable results. One study demonstrated effective decolonization of MRSA using 2 to 3 courses of a 5-day regimen consisting of mupirocin nasal ointment twice daily, chlorhexidine mouth rinse, and full-body wash with chlorhexidine soap.^[12] Other studies revealed that full-body chlorhexidine alone is not effective.^[34,35] Complete nasal decolonization with the use of topical mupirocin and oral vancomycin has been reported.^[36] Specifically, mupirocin has been demonstrated to be safe with minimal negative side effects, and oral vancomycin has a low-risk for developing vancomycin-resistant enterococci, unlike IV vancomycin.^[37] A 5-day course of twice daily mupirocin alone can be effective for decolonization.^[38] However, recolonization may occur as early as 1 week; therefore, surgery should be scheduled immediately after decolonization. Rapid recolonization, mupirocin resistance, persistence of gastrointestinal MRSA colonization without oral antibiotics, and lack of compliance with complex regimens are potential adverse events that may follow decolonization.^[9,12,26,38]

Prophylactic use of antibiotics in MRSA carriers is not without consequences. The antibiotic resistance of *S. aureus* has been demonstrated to be a result of selective pressure of antibiotics.^[39,40] It has been shown that both CA-MRSA and HA-MRSA are associated with previous use of particular antimicrobial prescriptions given in the community in the past 1 year.^[40] The highest risk exists with fluoroquinolones, although cephalosporins and macrolides also present an increased risk.^[40-42] Proper and limited use of antibiotics throughout the community can reduce CA-MRSA and HA-MRSA infections. One study demonstrated that MRSA colonization rates actually increased in its patient population after postoperative antibiotic therapy for sinus surgery, likely as a result of the removal of methicillin-sensitive *S. aureus* allowing for the proliferation of MRSA.^[43] Treatment of MRSA infections should be based on culture and sensitivity, and empiric therapy be based on antibiotics that have demonstrated success in that community.⁴

The use of prophylactic antibiotics in MRSA carriers is well supported in surgical patients with head and neck cancer because of their long hospitalization, age, and an immunocompromised state.^[13] Indications for preoperative antibiotic use in septorhinoplasty include prophylaxis to prevent septicemia in patients with valvular heart disease and those who are immunocompromised.^[6] In addition, patients with complex revision septorhinoplasties requiring free tissue transfers have been shown to benefit from prophylactic antibiotics because of their greater risk of infection.^[44] However, patients undergoing endonasal septorhinoplasty with autologous cartilage grafts have not been shown to benefit from reduced infection rates with prophylactic antibiotics.^[2] When nasal packing is used, it should be supplemented with antibiotic ointment and removed as early as indicated.^[6] Abscesses, which may form as a result of nasal packing, should be incised if they are not draining spontaneously.^[25] Although it has been suggested that systemic antibiotics be provided to supplement unusually long nasal packing times to avoid septic shock,⁶ multiple studies have shown that the onset of toxic shock syndrome is not delayed by antibiotic administration.^[2] In a review of reported MRSA-associated septorhinoplasty infections, patients were shown to respond well to culture-driven susceptible antibiotic regimens, resulting in minimal to attributable long-term functional or cosmetic consequences.^[4,9]

Currently, there are no standards for MRSA decolonization before septorhinoplasty. Due to the low incidence of MRSA colonization and the low incidence of MRSA-associated infections in septorhinoplasty, there is inadequate evidence to suggest any benefit of preoperative MRSA screening or decolonization, although some authors have recommended screening and topical mupirocin for colonized patients.^[5,8] In the setting of an initial or complicated revision rhinoplasty in patients at high risk for MRSA infection, the necessity of such an elective procedure should be considered on the basis of the guidelines discussed in this article. The purpose of this case report is to contribute to the body of literature if the incidence of this complication increases. In such circumstances, consideration may need to be given to preoperative screening, decolonization with mupirocin with or without systemic antibiotics, followed by surgery within 1 week of decolonization to minimize the risk of recolonization, as discussed above.^[4,5,44] Currently, careful case selection and treatment of any MRSA-associated infections postoperatively should continue to be the standard of care, with the literature only demonstrating benefit in preoperative antibiotics in patients with valvular heart disease, those in immunocompromised states, and those undergoing complicated revision septorhinoplasty with free-tissue transfers.^[6,44] The treatment of MRSA-associated septorhinoplasty infections is incision and drainage of the indicated areas with concurrent culture and sensitivity testing. Empiric antibiotic therapy followed by sensitivity-specific regimens should be administered, with consideration of infectious disease consultation. Provided careful consideration is given to infectious complications, septorhinoplasty can continue to be a safe and cosmetically enhancing procedure.

REFERENCES

1. Bhattacharyya N. Ambulatory sinus and nasal surgery in the United States: demographics and perioperative outcomes. *Laryngoscope*, 2010; 120: 635-638.
2. Rajan GP, Fergie N, Fischer U, Romer M, Radivojevic V, Hee GK. Antibiotic prophylaxis in septorhinoplasty? A prospective, randomized study. *Plast Reconstr Surg*, 2005; 116: 1995- 1998.
3. Jarvis WR, Jarvis AA, Chinn RY. National prevalence of methicillin-resistant *Staphylococcus aureus* in inpatients at United States health care facilities, 2010. *Am J Infect Control*, 2012; 40: 194-200.
4. Abuzeid WM, Brandt MG, Moyer JS, Baker SR. Methicillin-resistant *Staphylococcus aureus*-associated infections following septorhinoplasty. *Facial Plast Surg*, 2012; 28: 354-357.

5. Angelos PC, Wang TD. Methicillin-resistant *Staphylococcus aureus* infection in septorhinoplasty. *Laryngoscope*, 2010;120: 1309-1311.
6. Georgiou I, Farber N, Mendes D, Winkler E. The role of antibiotics in rhinoplasty and septoplasty: a literature review. *Rhinology*, 2008; 46: 267-270.
7. Butterly A, Schmidt U, Wiener-Kronish J. Methicillin-resistant *Staphylococcus aureus* colonization, its relationship to nosocomial infection, and efficacy of control methods. *Anesthesiology*, 2010; 113: 1453-1459.
8. Kalra L, Camacho F, Whitener CJ, et al. Risk of methicillin-resistant *Staphylococcus aureus* surgical site infection in patients with nasal MRSA colonization. *Am J Infect Control*, 2013; 41: 1253-1257.
9. Nicholas BD, Bhargava G, Hatipoglu A, et al. Preoperative prevalence of methicillin-resistant *Staphylococcus aureus* (MRSA) colonization in patients undergoing intranasal surgery. *Med Sci Monit*, 2010; 16: CR365-CR368.
10. Perry K. MRSA nasal abscess after elective septorhinoplasty. 2012. Available at: <http://www.researchposters.com/Posters/AAOHNSF/AAO2012/SP110.pdf>. Accessed March 9, 2015.
11. Cabouli JL, Guerrissi JO, Mileto A, Cerisola JA. Local infection following aesthetic rhinoplasty. *Ann Plast Surg*, 1986; 17: 306-309.
12. Buehlmann M, Frei R, Fenner L, Dangel M, Fluckiger U, Widmer AF. Highly effective regimen for decolonization of methicillin-resistant *Staphylococcus aureus* carriers. *Infect Control Hosp Epidemiol*, 2008; 29: 510-516.
13. Sharma A, Philpott C, Pope L, McKiernan D. Methicillin resistant *Staphylococcus aureus*: is it a problem for nasal surgery? *J Laryngol Otol*, 2007; 121: 415-418.
14. Panlilio AL, Culver DH, Gaynes RP, et al. Methicillin-resistant *Staphylococcus aureus* in U.S. hospitals, 1975-1991. *Infect Control Hosp Epidemiol*, 1992; 13: 582-586.
15. Lin YC, Lauderdale TL, Lin HM, et al. An outbreak of methicillin-resistant *Staphylococcus aureus* infection in patients of a pediatric intensive care unit and high carriage rate among health care workers. *J Microbiol Immunol Infect*, 2007; 40: 325-334.
16. Zervou FN, Zacharioudakis IM, Ziakas PD, Rich JD, Mylonakis E. Prevalence of and risk factors for methicillin-resistant *Staphylococcus aureus* colonization in HIV infection: a meta-analysis. *Clin Infect Dis*, 2014; 59: 1302-1311.
17. Hidron AI, Kourbatova EV, Halvosa JS, et al. Risk factors for colonization with methicillin-resistant *Staphylococcus aureus* (MRSA) in patients admitted to an urban hospital: Emergence of community-associated MRSA nasal carriage. *Clin Infect Dis*, 2005; 41: 159-166.
18. Furuno JP, McGregor JC, Harris AD, et al. Identifying groups at high risk for carriage of antibiotic-resistant bacteria. *Arch Intern Med*, 2006; 166: 580-585.
19. Lucet JC, Chevret S, Durand-Zaleski I, Chastang C, Régnier B; Multicenter Study Group. Prevalence and risk factors for carriage of methicillin-resistant *Staphylococcus aureus* at admission to the intensive care unit: results of a multicenter study. *Arch Intern Med*, 2003; 163: 181.
20. Mukherjee DV, Herzig CT, Jeon CY, et al. Prevalence and risk factors for *Staphylococcus aureus* colonization in individuals entering maximum-security prisons. *Epidemiol Infect*, 2014; 142: 484-493.
21. Gilbert M, MacDonald J, Gregson D, et al. Outbreak in Alberta of community-acquired (USA300) methicillin-resistant *Staphylococcus aureus* in people with a history of drug use, homelessness or incarceration. *CMAJ*, 2006; 175: 149.

22. Aiello AE, Lowy FD, Wright LN, Larson EL. Methicillin-resistant *Staphylococcus aureus* among US prisoners and military personnel: Review and recommendations for future studies. *Lancet Infect Dis.*, 2006; 6: 335-341.
23. Centers for Disease Control and Prevention. Methicillin-resistant *Staphylococcus aureus* infections among competitive sports participantsdColorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. *MMWR Morb Mortal Wkly Rep.*, 2003; 52: 793.
24. Klevens RM, Morrison MA, Nadle J, et al; Active Bacterial Core surveillance (ABCs) MRSA Investigators. Invasive methicillin-resistant *Staphylococcus aureus* infections in the United States. *JAMA*, 2007; 298: 1763.
25. Gryskiewicz JM, Hattef DA, Bullocks JM, Stal S. Problems in rhinoplasty. *Clin Plast Surg.*, 2010; 37: 389-399.
26. Kauffman CA, Terpenning MS, He X, et al. Attempts to eradicate methicillin-resistant *Staphylococcus aureus* from a long-term-care facility with the use of mupirocin ointment. *Am J Med.*, 1993; 94: 371-378.
27. Rudresh MS, Ravi GS, Motagi A, Alex AM, Sandhya P, Navaneeth BV. Prevalence of mupirocin resistance among staphylococci, its clinical significance and relationship to clinical use. *J Lab Physicians*, 2015; 7: 103-107.
28. Mest DR, Wong DH, Shimoda KJ, Mulligan ME, Wilson SE. Nasal colonization with methicillin-resistant *Staphylococcus aureus* on admission to the surgical intensive care unit increases the risk of infection. *Anesth Analg*, 1994; 78: 644-650.
29. Ridgway JP. Clinical significance of methicillin-resistant *Staphylococcus aureus* colonization on hospital admission: one-year infection risk. *PLoS One*, 2013; 8: e79716.
30. Gupta K, Strymish J, Abi-Haidar Y, Williams SA, Itani KM. Preoperative nasal methicillin-resistant *Staphylococcus aureus* status, surgical prophylaxis, and risk-adjusted postoperative outcomes in veterans. *Infect Control Hosp Epidemiol*, 2011; 32: 791-796.
31. Mertz D, Frei R, Periat N, et al. Exclusive *Staphylococcus aureus* throat carriage: at-risk populations. *Arch Intern Med.*, 2009; 169: 172-178.
32. Warnke P, Frickmann H, Ottl P, Podbielski A. Nasal screening for MRSA: different swabs e different results! *PLoS One*, 2014; 9: e111627.
33. Warnke P, Harnack T, Ottl P, Kundt G, Podbielski A. Nasal screening for *Staphylococcus aureus*ddaily routine with improvement potentials. *PLoS One*. 2014; 9: e89667.
34. Whitman TJ, Herlihy RK, Schlett CD, et al. Chlorhexidine-impregnated cloths to prevent skin and soft-tissue infection in Marine recruits: a cluster-randomized, double-blind, controlled effectiveness trial. *Infect Control Hosp Epidemiol*, 2010; 31: 1207-1215.
35. Wendt C, Schinke S, Württemberger M, Oberdorfer K, Bock-Hensley O, von Baum H. Value of whole-body washing with chlorhexidine for the eradication of methicillin-resistant *Staphylococcus aureus*: a randomized, placebo-controlled, double-blind clinical trial. *Infect Control Hosp Epidemiol*, 2007; 28: 1036-1043.
36. Maraha B, van Halteren J, Verzijl JM, Wintermans RG, Buiting AG. Decolonization of methicillin-resistant *Staphylococcus aureus* using oral vancomycin and topical mupirocin. *Clin Microbiol Infect*, 2002; 8: 671-675.
37. Gerding DN. Is there a relationship between vancomycin-resistant enterococcal infection and *Clostridium difficile* infection? *Clin Infect Dis.*, 1997; 25: S206-S210.
38. Hill RL, Duckworth GJ, Casewell MW. Elimination of nasal carriage of methicillin-resistant *Staphylococcus aureus* with mupirocin during a hospital outbreak. *J Antimicrob Chemother*, 1988; 22: 377-384.
39. Shorr AF. Epidemiology of staphylococcal resistance. *Clin Infect Dis.*, 2007; 45: S171-S176.

40. Schneider-Lindner V, Delaney JA, Dial S, Dascal A, Suissa S. Antimicrobial drugs and community-acquired methicillin-resistant *Staphylococcus aureus*, United Kingdom. *Emerg Infect Dis.*, 2007; 13: 994.
41. Couderc C, Jolivet S, Thiébaud AC, et al; Antibiotic Use and *Staphylococcus aureus* Resistant to Antibiotics (ASAR) Study Group. Fluoroquinolone use is a risk factor for methicillin-resistant *Staphylococcus aureus* acquisition in long-term care facilities: a nested case-case-control study. *Clin Infect Dis.*, 2014; 59(2): 206.
42. Hill DA, Herford T, Parratt D. Antibiotic usage and methicillin-resistant *Staphylococcus aureus*: an analysis of causality. *J Antimicrob Chemother*, 1998; 42: 676.
43. Jiang RS, Jang JW, Hsu CY. Post-functional endoscopic sinus surgery methicillin-resistant *Staphylococcus aureus* sinusitis. *Am J Rhinol*, 1999; 13: 273-277.
44. Pirsig W, Schäfer J. The importance of antibiotic treatment in functional and aesthetic rhinosurgery. *Rhinol Suppl.*, 1988; 4: 3-11.